Compare Illumina, Inc. (ILMN) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Intuit Inc. — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Intuit Inc. trades at $279.58 (market cap $80.37B). The key difference: Intuit Inc. is far larger — about 2.9× Illumina, Inc.'s market cap, and Intuit Inc. pays a 1.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | INTU | |
|---|---|---|
Market Cap | $27.94B | $80.37B |
Sector | Health | Technology |
52-Week High | $194.33 | $807.39 |
52-Week Low | $91.00 | $255.07 |
Enterprise Value | $29.33B | $78.83B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Intuit (INTU) trades at $293.82, up 0.94% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. The stock faces headwinds from legal investigations into pricing disclosures, contributing to a 20% drop from 2025 highs, but maintains a consensus analyst price target of $423.11 with 71% buy ratings.
The outlook is mixed: strong revenue growth and AI-driven product expansion support upside, but legal risks and competitive pressures pose significant threats. Investors should weigh the company's solid financials against ongoing litigation and market sentiment shifts for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
